DURABILITY OF COMPLETE RESPONSE AFTER BLINATUMOMAB THERAPY FOR REFRACTORY/RELAPSED AGGRESSIVE B‐CELL NON‐HODGKIN LYMPHOMA. (12th June 2019) - Viardot, A.; Hess, G.; Bargou, R.; Morley, N.J.; Gritti, G.; Iskander, K.; Cohan, D.; Zhang, A.; Franklin, J.; Coyle, L.